Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any Waardenburg syndrome type 2 in which the cause of the disease is a mutation in the SOX10 gene.
Features include always present findings: Blue irides, Ocular albinism, White forelock, and Inner ear hearing loss (sensorineural hearing impairment) and others; and sometimes findings: Anosmia. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Cerebral hypomyelination, Intellectual disability, Global developmental delay |
Ears | 3 | Dilated vestibule of the inner ear, Abnormal morphology of the vestibule of the inner ear, Inner ear hearing loss (sensorineural hearing impairment) |
Eyes | 2 | Nystagmus, Ocular albinism |
Skin | 1 | Hypopigmented skin patches |
Muscles | 1 | Axial hypotonia |
SOX10 function has not been fully characterized.
Waardenburg syndrome type 2E is associated with mutations in the SOX10 gene on chromosome 22.
Genetic testing for SOX10 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Waardenburg syndrome type 2E has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
109 publications have been identified in PubMed for Waardenburg syndrome type 2E. Kisho has analyzed 83 by research type. Research spans Review / Meta-Analysis (54%), Case Report / Case Series (13%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 54% |
Patient case studies | 11 | 13% |
Laboratory research | 11 | 13% |
Disease patterns and progression | 8 | 10% |
Other research | 4 | 5% |
New treatment approaches | 3 | 4% |
Testing and diagnosis research | 1 | 1% |
Tirthani E (2026). [PMID: 33232100](https://pubmed.ncbi.nlm.nih.gov/33232100/). *Unknown Journal*. [Basic Science / Preclinical]
Watras T (2026). [PMID: 32119424](https://pubmed.ncbi.nlm.nih.gov/32119424/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Tafti D (2026). [PMID: 30422590](https://pubmed.ncbi.nlm.nih.gov/30422590/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Shah SS (2026). [PMID: 34662020](https://pubmed.ncbi.nlm.nih.gov/34662020/). *Unknown Journal*. [Basic Science / Preclinical]
Szymanowski AR (2026). [PMID: 41206204](https://pubmed.ncbi.nlm.nih.gov/41206204/). *Med Clin North Am*. [Review / Meta-Analysis]
Critelli M 2nd (2026). [PMID: 41960002](https://pubmed.ncbi.nlm.nih.gov/41960002/). *Cureus*. [Review / Meta-Analysis]
Sadri RA (2026). [PMID: 29083713](https://pubmed.ncbi.nlm.nih.gov/29083713/). *Unknown Journal*. [Epidemiology / Natural History]
Manolis TA (2026). [PMID: 41350148](https://pubmed.ncbi.nlm.nih.gov/41350148/). *Eur J Intern Med*. [Review / Meta-Analysis]
Patel JN (2026). [PMID: 41429672](https://pubmed.ncbi.nlm.nih.gov/41429672/). *Int Ophthalmol Clin*. [Review / Meta-Analysis]
Rodriguez-Beato FY (2026). [PMID: 32965909](https://pubmed.ncbi.nlm.nih.gov/32965909/). *Unknown Journal*. [Other]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 6:47 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Waardenburg syndrome type 2E